Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.45 |
| ▸ | PDE4A | P27815 | 9/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levacetylleucine SCHEMBL7084218 | 1.00 | LMNA (0.45) | LMNAPDE4BPDE4CPDE4APDE4D | |
| Acetylleucine SCHEMBL20474775 | 1.00 | LMNA (0.45) | LMNAPDE4BPDE4CPDE4APDE4D | |
| Levacetylleucine SCHEMBL756572 | 1.00 | LMNA (0.45) | LMNAPDE4BPDE4CPDE4APDE4D | |
| Levacetylleucine SCHEMBL21229236 | 1.00 | LMNA (0.45) | LMNAPDE4BPDE4CPDE4APDE4D | |
| Levacetylleucine SCHEMBL702915 | 0.94 | PDE4B (0.43) | LMNAPDE4BPDE4CPDE4APDE4D | |
| Levacetylleucine SCHEMBL703860 | 0.89 | FOLH1 (0.42) | LMNAPDE4BPDE4CPDE4APDE4D | |
| Leucine SCHEMBL18074074 | 0.87 | PDE4B (0.48) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Leucine SCHEMBL18074075 | 0.87 | PDE4B (0.48) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL2670612 | 0.87 | LMNA (0.47) | LMNAPDE4BPDE4CPDE4APDE4D | |
| SCHEMBL21250512 | 0.85 | FOLH1 (0.45) | LMNAPDE4BPDE4CPDE4APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118851979-A | Preparation method of apremilast | 潍坊市海欣药业有限公司 | 2024-10-29 | — | — | CN | claimed |
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | AMGEN INC. (US) | 2022-03-01 | — | — | US | claimed |
| US-10913717-B2 | Solid state forms of N-[2-[(I S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methyl sulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-L H-isoindol-4-yl]acetamide and process for preparation thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2021-02-09 | — | — | US | claimed |
| US-20210023051-A1 | (+)-2-[1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHYLSULFONYLETHYL]- 4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | AMGEN INC. | 2021-01-28 | — | — | US | claimed |
| US-10781173-B2 | Method for preparing apremilast | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2020-09-22 | — | — | US | claimed |
| US-20200109114-A1 | SOLID STATE FORMS OF N-[2-[(I S)-1 -(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYL SULFONYL)ETHYL]-2,3-DIHYDRO-1,3-DIOXO-L H-ISOINDOL-4-YL]ACETAMIDE AND PROCESS FOR PREPARATION THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2020-04-09 | — | — | US | claimed |
| US-20190248740-A1 | METHOD FOR PREPARING APREMILAST | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2019-08-15 | — | — | US | claimed |
| EP-3524242-A1 | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | Celgene Corporation (US) | 2019-08-14 | — | — | EP | claimed |
| EP-2420490-B1 | Method for the preparation of (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CELGENE CORP (US) | 2016-07-20 | — | — | EP | claimed |
| EP-2420490-A1 | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof | CELGENE CORPORATION (US) | 2012-02-22 | — | — | EP | claimed |
| US-20050192336-A1 | Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor | AMGEN INC. | 2005-09-01 | — | — | US | claimed |
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | AMGEN INC. | 2003-10-02 | — | — | US | claimed |
| EP-3619195-B1 | NOVEL PROCESS TO PREPARE N-[2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULPHONYL) ETHYL]-1, 3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL]ACETAMIDE | UNICHEM LAB LTD (IN) | 2025-07-23 | — | — | EP | disclosed |
| CN-119390623-A | Racemization preparation method of apremilast and intermediate thereof | 菏泽皓元医药科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-118851979-A | Preparation method of apremilast | 潍坊市海欣药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-3702347-B1 | PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE | AMGEN EUROPE GMBH (CH) | 2023-11-08 | — | — | EP | disclosed |
| US-20050192336-A1 | Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor | AMGEN INC. | 2005-09-01 | — | — | US | disclosed |
| EP-1485087-A1 | (+)-2- 1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | AMGEN INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003080049-A1 | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | PDE4A, PDE2A, PDE3A | LMNA 1170/4885PDE4B 6/4885PDE4C 8/4885 |
| US-10913717-B2 | Solid state forms of N-[2-[(I S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methyl sulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-L H-isoindol-4-yl]acetamide and process for preparation thereof | SULT1A1, SULT2A1, SULT1E1 | LMNA 1467/4885PDE4B 2424/4885PDE4C 2986/4885 |
| US-20200109114-A1 | SOLID STATE FORMS OF N-[2-[(I S)-1 -(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYL SULFONYL)ETHYL]-2,3-DIHYDRO-1,3-DIOXO-L H-ISOINDOL-4-YL]ACETAMIDE AND PROCESS FOR PREPARATION THEREOF | SULT1A1, SULT2A1, SULT1E1 | LMNA 1467/4885PDE4B 2424/4885PDE4C 2986/4885 |
| US-20050192336-A1 | Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor | IL4, PTGER4, PDE4A | LMNA 3162/4885PDE4B 7/4885PDE4C 11/4885 |
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | PDE4A, PDE4B, PDE2A | LMNA 1491/4885PDE4B 2/4885PDE4C 7/4885 |
| US-10781173-B2 | Method for preparing apremilast | CMA1, ACE, AGT | LMNA 1064/4885PDE4B 3492/4885PDE4C 3783/4885 |
| US-20190248740-A1 | METHOD FOR PREPARING APREMILAST | CMA1, ACE, AGT | LMNA 1064/4885PDE4B 3492/4885PDE4C 3783/4885 |
| US-20210023051-A1 | (+)-2-[1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHYLSULFONYLETHYL]- 4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | PDE4A, PDE4B, PDE2A | LMNA 1491/4885PDE4B 2/4885PDE4C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.